Pilot Introduction of Oxytocin in the Unijectª Injection System During Active Management of the Third Stage of Labor (AMTSL) at the Institutional Level in Honduras

Publish Date: August 2012
Author: PATH
Language: English, Spanish

This report evaluates the acceptability and feasibility of introducing oxytocin Uniject for active management of the third stage of labor. The Ministry of Health of Honduras (MOH) identified oxytocin in the Uniject™ injection system (oxytocin in Uniject) as a potential part of its strategy to address high mortality from postpartum hemorrhage (PPH) due to the system’s benefits of being single-dose, prefilled, non-reusable, and easy to use.

As a way to evaluate the feasibility and acceptability of introducing oxytocin in Uniject into the health system, the MOH—in collaboration with MCHIP, PATH, ChildFund Honduras, and USAID/Honduras—conducted a pilot introduction of oxytocin in Uniject for use during AMTSL at the institutional level as part of the ongoing PPH prevention initiative in Honduras. The pilot evaluation demonstrated high levels of acceptability of oxytocin in Uniject and relative ease in training health care providers in its use, indicating that its introduction for use by most cadres should be relatively easy.

Attachment	Size
Honduras Oxytocin Pilot Report_English.pdf	905.23 KB
Honduras Oxytocin Pilot Report_Spanish.pdf	1017.38 KB